Recent advances in the field of obesity treatment have presented a novel candidate known as ALLUVI Retatrutide. This substance is a {highlyeffective GLP-1 receptor agonist, engineered to stimulate the effects of natural glucagon-like peptide-1. Retatrutide has shown remarkable results in clinical trials, exhibiting significant losses in body weight